Labcorp (NYSE:LH) Hits New 52-Week High Following Better-Than-Expected Earnings

Labcorp Holdings Inc. (NYSE:LH) reached a new 52-week high on Wednesday following a stronger than expected earnings report. The company traded as high as $371.00 and last traded at $364.2510, with a volume of 777,458 shares trading hands. The stock had previously closed at $331.17.

The medical research company reported $4.78 EPS for the quarter, beating analysts’ consensus estimates of $4.64 by $0.14. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The company had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the previous year, the business posted $4.18 earnings per share. Labcorp’s quarterly revenue was up 6.9% on a year-over-year basis.

Labcorp Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Tuesday, November 24th will be given a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 0.8%. The ex-dividend date is Tuesday, November 24th. Labcorp’s payout ratio is 23.82%.

Trending Headlines about Labcorp

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Q3 results exceeded expectations: Adjusted EPS was $4.78, above the $4.64 consensus estimate, while revenue reached $3.81 billion versus expectations of $3.76 billion. Revenue increased 6.9% year over year, and adjusted earnings rose from $4.18 a year earlier. LH Stock Rises on Q3 Earnings and Revenue Beat, 2026 View Up
• Positive Sentiment: Full-year guidance was raised: Labcorp now expects enterprise revenue growth of 5.9% to 6.7% in 2026 and adjusted EPS of $18.30 to $18.70, signaling management’s confidence in sustained demand and profitability. Labcorp Boosts FY26 Outlook
• Positive Sentiment: Both operating segments grew: Diagnostics Laboratories revenue rose 6.5% to $2.95 billion, while Biopharma Laboratory Services revenue increased 8.5% to $866.7 million. Margin expansion further supported the earnings beat.
• Positive Sentiment: Growth initiatives continued: Labcorp announced or completed four transactions, including the acquisition of MLM Medical Labs and agreements involving BioReference Health, Myriad Genetics and Millennium Health. The FDA also approved the company’s PGDx elio tissue complete CDx companion diagnostic for advanced melanoma. Labcorp Reports Strong 2026 Third Quarter Results
• Neutral Sentiment: Labcorp is expanding access to FDA-approved HPV screening tests through a partnership with Waters, potentially supporting future diagnostics adoption, although the impact is expected later in 2026. Waters and Labcorp Expand Access to HPV Screening Tests
• Negative Sentiment: Reported insider activity remains a potential overhang: insiders made no open-market purchases and completed multiple sales during the past six months. These transactions do not necessarily reflect management’s near-term outlook.

Analyst Ratings Changes

A number of analysts have weighed in on LH shares. Piper Sandler increased their price objective on Labcorp from $300.00 to $309.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 4th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and issued a $306.00 target price on shares of Labcorp in a report on Friday, July 31st. JPMorgan Chase & Co. upped their price target on Labcorp from $330.00 to $360.00 and gave the stock an “overweight” rating in a research note on Monday, August 3rd. UBS Group increased their price target on Labcorp from $361.00 to $380.00 and gave the stock a “buy” rating in a report on Friday, September 11th. Finally, Weiss Ratings upgraded shares of Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a research report on Wednesday, October 21st. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $337.73.

Insider Transactions at Labcorp

In related news, CEO Adam Schechter sold 4,669 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $320.37, for a total transaction of $1,495,807.53. Following the completion of the transaction, the chief executive officer directly owned 102,565 shares of the company’s stock, valued at $32,858,749.05. This represents a 4.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kerrii Anderson sold 3,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $318.02, for a total transaction of $954,060.00. Following the completion of the sale, the director owned 6,563 shares of the company’s stock, valued at approximately $2,087,165.26. The trade was a 31.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,593 shares of company stock worth $2,733,295 over the last ninety days. 0.84% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Labcorp

A number of large investors have recently modified their holdings of the business. Signaturefd LLC lifted its holdings in shares of Labcorp by 4.9% in the 3rd quarter. Signaturefd LLC now owns 687 shares of the medical research company’s stock valued at $212,000 after buying an additional 32 shares during the period. CoreCap Advisors LLC raised its position in Labcorp by 13.8% in the third quarter. CoreCap Advisors LLC now owns 289 shares of the medical research company’s stock worth $89,000 after acquiring an additional 35 shares in the last quarter. Krilogy Financial LLC raised its position in Labcorp by 2.4% in the third quarter. Krilogy Financial LLC now owns 1,590 shares of the medical research company’s stock worth $502,000 after acquiring an additional 37 shares in the last quarter. V Square Quantitative Management LLC lifted its holdings in Labcorp by 1.7% in the first quarter. V Square Quantitative Management LLC now owns 2,418 shares of the medical research company’s stock valued at $645,000 after acquiring an additional 40 shares during the period. Finally, Meeder Advisory Services Inc. lifted its holdings in Labcorp by 4.5% in the first quarter. Meeder Advisory Services Inc. now owns 1,021 shares of the medical research company’s stock valued at $272,000 after acquiring an additional 44 shares during the period. 95.94% of the stock is owned by hedge funds and other institutional investors.

Labcorp Trading Up 10.7%

The company has a market cap of $29.74 billion, a price-to-earnings ratio of 30.25, a P/E/G ratio of 1.88 and a beta of 0.87. The business has a fifty day simple moving average of $321.16 and a 200 day simple moving average of $285.95. The company has a quick ratio of 1.53, a current ratio of 1.80 and a debt-to-equity ratio of 0.69.

About Labcorp

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.